Skip to content

Released Mar 17, 2014, after the close

10-K filed Mar 17, 2014, 76 days after period end · 0001390478-14-000016

Q4 2013 · 10-K
Revenue$1.44M±0.0% vs Q4 2012−33.7% vs Q3 2013
Net Income-$5.52MN/M vs Q4 2012N/M vs Q3 2013
EPS, diluted—
Gross Profit$1,229,000±0.0%
Operating Incomederived-$6,999,000—
Operating Cash Flowderived-$8,492,000N/M
Free Cash Flowderived-$8,258,000—
Margins · derived
Gross margin85.6%±0.0 pt vs Q4 2012
Operating margin-487.4%
Net margin-384.1%+986.2 pt vs Q4 2012

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2013Q4 2012Q4 2011derived from reported figuresQ4 2010derived from reported figures
Revenue$1.44M$1.44M——
Net Income-$5.52M-$19.68M$1.59M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR